Precursor B-cell acute lymphoblastic leukemia
MONDO:0020511The most frequent type of acute lymphoblastic leukemia. Approximately 75% of cases occur in children under six years of age. This is a good prognosis leukemia. In the pediatric age group the complete remission rate is approximately 95% and the disease free survival rate is 70%. Approximately 80% of children appear to be cured. In the adult age group the complete remission rate is 60-85%. (WHO, 2001)
Also known as: B acute lymphoblastic leukaemia, B acute lymphoblastic leukemia, B cell acute lymphocytic leukaemia, B cell acute lymphocytic leukemia, B-ALL, B-cell acute lymphoblastic leukaemia, B-cell acute lymphoblastic leukemia, B-cell acute lymphocytic leukaemia
2114 clinical trials for this condition and its sub-types, 66 tagged with Precursor B-cell acute lymphoblastic leukemia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Precursor B-cell acute lymphoblastic leukemia
-
B-cell adult acute lymphocytic leukemia 12 trials
-
Leukemia shot could replace long IV drips
Disease control Not yet recruitingThis study tests if a shot (subcutaneous) of the drug blinatumomab works as well as the standard IV drip for adults with a certain type of leukemia (Ph-negative B-cell ALL). About 560 people who are in remission after initial chemo will get either the shot or the IV, along with m…
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can a new combo drug tame childhood leukemia that Won't quit?
Disease control Not yet recruitingThis trial is investigating whether a new drug called sonrotoclax, when combined with other anti-cancer medicines, is safe and effective for children and adolescents with acute myeloid leukemia (AML) or B-cell acute lymphoblastic leukemia (ALL) that has returned or not responded …
Phase 1/2 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New combo therapy aims to treat leukemia without harsh chemo
Disease control Not yet recruitingThis study tests whether combining two drugs, inotuzumab and blinatumomab, is safe and effective for adults newly diagnosed with B-cell acute lymphoblastic leukemia (B-ALL). The trial includes 26 people aged 18 and older who are either 55+ or cannot tolerate standard chemotherapy…
Phase 1/2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a cheaper copy of a leukemia drug work just as well?
Disease control Not yet recruitingThis phase 3 trial is testing whether a new drug called BLB101 works as well as the approved drug Blincyto for adults with a type of blood cancer called B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. The study will compare how the drugs are …
Phase 3 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
In-Body CAR-T: a new shot at fighting blood cancers?
Disease control Not yet recruitingThis early study tests a new treatment called U96 for people with B-cell leukemia or lymphoma that has come back or not responded to standard therapy. U96 is a gene therapy given as a single infusion that aims to create cancer-fighting CAR-T cells inside the patient's own body. T…
Phase 1 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New CAR-T therapy aims to tackle tough blood cancers
Disease control Not yet recruitingThis trial tests a new treatment called SHB-02-CD19, which uses a patient's own immune cells engineered to attack cancer cells that have a protein called CD19. It is for children and adults with B-cell cancers (like leukemia or lymphoma) that have come back or not responded to at…
Phase 1/2 • Sponsor: Sheba Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Promising immunotherapy trial aims to replace harsh chemo for kids with relapsed leukemia
Disease control Not yet recruitingThis phase 3 trial tests two immunotherapy drugs, inotuzumab and blinatumomab, in 750 children with relapsed B-cell acute lymphoblastic leukemia. The goal is to replace toxic chemotherapy with targeted, less harmful treatments to improve survival and reduce side effects. Particip…
Phase 3 • Sponsor: Charite University, Berlin, Germany • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug combo aims to finish off hidden leukemia cells in high-risk patients
Disease control Not yet recruitingThis study tests a new drug called BEBT-908 combined with chemotherapy in adults with a rare, high-risk form of acute lymphoblastic leukemia (ALL) who are in remission but still have tiny amounts of cancer cells detectable. The goal is to see if the combo can clear those leftover…
Phase 2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Personalized dosing may improve stem cell transplant survival in blood cancer patients
Knowledge-focused Not yet recruitingThis study compares survival and other outcomes in patients with acute leukemia or myelodysplastic syndrome who received a stem cell transplant with a personalized dose of an immune-suppressing drug (r-ATG) to similar patients from a large registry who received standard treatment…
Sponsor: Miltenyi Biomedicine GmbH • Aim: Knowledge-focused
Last updated Jul 30, 2026 00:00 UTC
-
Italian study to track CAR-T success in leukemia patients
Knowledge-focused Not yet recruitingThis observational study will follow 107 children and adults with B-cell acute lymphoblastic leukemia who are treated with approved CAR-T cell therapies in Italy. Researchers will collect data from medical records to see how many patients achieve a response. The goal is to unders…
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Scientists hunt for immune weak spots in B-Cell cancers
Knowledge-focused Not yet recruitingThis study looks at two immune-related proteins, CD274 and CD276, in people newly diagnosed with B-cell cancers like leukemia and lymphoma. Researchers will use a blood test to measure these proteins and see how they help cancer hide from the immune system. The goal is to find be…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC